DESCRIPTION:
NEXAVIR® Injection (liver derivative complex) is a sterile solution containing 25.5 mg liver derivative complex per mL in sterile water for injection.

NEXAVIR® Injection is composed of peptides and amino acids. The product contains no protein and does not exhibit anti-anemia activity.

NEXAVIR® Injection also contains as inactive ingredients: phenol 0.5% sterile water for injection, pH is adjusted with hydrochloric acid or sodium hydroxide when necessary.

CLINICAL PHARMACOLOGY:
The specific action of NEXAVIR® is to enhance the resolution of inflammation and edema. In the late 1920's it was demonstrated that liver was of benefit to patients suffering from acne vulgaris. As a consequence, various techniques were employed for isolating the active "factor" from liver. Studies published in the late 1930's and early 1940's showed activity in a specially purified liver fraction. During subsequent years refinements in the isolation of the active material led to the marketing of NEXAVIR®.

Initially it was thought that the primary action of NEXAVIR® was on the capillaries and precapillary sphincters. However, it is now believed that this effect is a secondary one and that the primary action of NEXAVIR® is in response to injury at the cellular level. The capillary changes observed following administration of NEXAVIR® appear to be part of a more fundamental anti-inflammatory effect. In the normal animal no consistent pharmacodynamic action has been demonstrated for NEXAVIR®, in particular there is no effect on the systemic blood pressure, no action on the autonomic nervous system and no alteration in prothrombin, coagulation or bleeding times. It is concluded that the specific action of the product is only apparent when tissues have been subjected to injury and when inflammation and edema are present.

INDICATIONS AND USAGE:
A wide range of dermatological clinical conditions benefit from NEXAVIR® therapy. The common denominator in these varied conditions is the presence of inflammation and edema. Favorable response to administration of NEXAVIR® in patients with acne vulgaris, papular or nodular lesions, lichenification, seborrheic dermatitis, urticaria and eczema, severe sunburn, and rosacea have been reported.

CONTRAINDICATIONS:
Contraindicated in patients with hypersensitivity or intolerance to liver or pork products.

WARNING:
Use with caution in patients suspected of being hypersensitive to liver or with other allergic diatheses.

PRECAUTIONS:
Drug Interactions:
NEXAVIR® contains tyramine and should not be administered to patients taking MAO inhibitors because hypertensive crisis may occur.

Carcinogenesis, Mutagenesis, Impairment of Fertility:
No long term animal studies have examined the carcinogenic or mutagenic potential of NEXAVIR®. NEXAVIR®'s effect upon reproductive capacity is unknown.

Pregnancy - Pregnancy Category C:
Animal reproduction studies have not been conducted with NEXAVIR®. It is also not known whether NEXAVIR® can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. NEXAVIR® should be given to a pregnant woman only if clearly needed.

Nursing Mothers:
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NEXAVIR® is administered to a nursing woman.

ADVERSE REACTIONS:
As with all injectable medications, local reactions may occur. Local reactions may include pain, rash, stinging, swelling, and erythema.
DRUG ABUSE AND DEPENDENCE:
The information on drug abuse and dependence is limited to uncontrolled data
derived from marketing experience. Such experience has revealed no evidence of
drug abuse and dependence associated with NEXAVIR® injection.

DOSAGE AND ADMINISTRATION:
For the management of skin disorders, the usual dose of NEXAVIR® is 2mL
administered daily or as indicated. The product is given by intramuscular or
subcutaneous injection only.

As with all parenteral drug products, NEXAVIR® should be inspected visually for
particulate matter and discoloration prior to administration, whenever solution and
container permit.

HOW SUPPLIED:
NEXAVIR® Injection (liver derivative complex, 25.5mg/mL) is a sterile, brown
solution.
20 mL multiple-dose vial NDC 10500-0815-13
Store at controlled room temperature 15°-30°C (59°-86°F)

REFERENCES:
   Derm. & Syph., 18:887, 1928. See also Sutton, R.L., and Sutton
   Acne Vulgaris in Tuberculosis Patients, Arch. Derm. & Syph.,
   45:959, 1942
   Med., 26:276, 1942
   Vasooconstrictor (Kutapressin), The Jour. of Ind. State Med. Asso.,
   45:497, 1952
   Letter, 20:5, 1952
   1952
8. Pensky, N. and Goldner, N.: Treatment of Refractory Acne with a
   Fractionated Type of Liver Extract, N.Y. State Jour. of Med. 53:2238,
11. Barkdale, Edwin E.: The Use of S-Factor of Liver Extract

Manufactured for:

nexCo Pharma
Houston, TX 77282-0023

By:
Hyaluron Inc
Burlington, MA 01803

BO0197F
Rev:2/05